Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Zhang Website

Shuling Zhang, M.D., Ph.D.

Selected Publications

1)  Simmons JK, Patel J, Michalowski A, Zhang S, Wei BR, Sullivan P, Gamache B, Felsenstein K, Kuehl WM, Simpson RM, Zingone A, Landgren O, Mock BA.
TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms.
Mol Oncol. 8: 261-72, 2014.
2)  Smrž D, Bandara G, Zhang S, Mock BA, Beaven MA, Metcalfe DD, Gilfillan AM.
A novel KIT-deficient mouse mast cell model for the examination of human KIT-mediated activation responses.
J. Immunol. Methods. 390: 52-62, 2013.
3)  Zhang S, Pruitt M, Tran D, Du Bois W, Zhang K, Patel R, Hoover S, Simpson RM, Simmons J, Gary J, Snapper CM, Casellas R, Mock BA.
B cell-specific deficiencies in mTOR limit humoral immune responses.
J. Immunol. 191: 1692-703, 2013.
4)  Wu JJ, Liu J, Chen EB, Wang JJ, Cao L, Narayan N, Fergusson MM, Rovira II, Allen M, Springer DA, Lago CU, Zhang S, DuBois W, Ward T, deCabo R, Gavrilova O, Mock B, Finkel T.
Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression.
Cell Rep. 4: 913-20, 2013.
5)  Zhang S, Readinger JA, DuBois W, Janka-Junttila M, Robinson R, Pruitt M, Bliskovsky V, Wu JZ, Sakakibara K, Patel J, Parent CA, Tessarollo L, Schwartzberg PL, Mock BA.
Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production.
Blood. 117: 1228-38, 2011.
6)  Smrz D, Kim MS, Zhang S, Mock BA, Smrzová S, DuBois W, Simakova O, Maric I, Wilson TM, Metcalfe DD, Gilfillan AM.
mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells.
Blood. 118: 6803-13, 2011.
7)  Zhang K, Kagan D, DuBois W, Robinson R, Bliskovsky V, Vass WC, Zhang S, Mock BA.
Mndal, a new interferon-inducible family member, is highly polymorphic, suppresses cell growth, and may modify plasmacytoma susceptibility.
Blood. 114: 2952-60, 2009.
8)  Mock B, Zhang S, Ramsay E, Bliskovsky V, Zhang K, Shi W, DuBois W.
Strategies for dissection complex traits associated with cancer: lessons from plasma cell tumors. In: AACR Education Book 2005.
Philadelphia: AACR; 2005. p. 273-276 [Book Chapter]
9)  Richardson JY, Ottolini MG, Pletneva L, Boukhvalova M, Zhang S, Vogel SN, Prince GA, Blanco JC.
Respiratory syncytial virus (RSV) infection induces cyclooxygenase 2: a potential target for RSV therapy.
J. Immunol. 174: 4356-64, 2005.
10)  Medvedev AE, Lentschat A, Kuhns DB, Blanco JC, Salkowski C, Zhang S, Arditi M, Gallin JI, Vogel SN.
Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections.
J. Exp. Med. 198: 521-31, 2003.
11)  Bliskovsky V, Ramsay ES, Scott J, DuBois W, Shi W, Zhang S, Qian X, Lowy DR, Mock BA.
Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene.
Proc. Natl. Acad. Sci. U.S.A. 100: 14982-7, 2003.
12)  Zhang S, Qian X, Redman C, Bliskovski V, Ramsay ES, Lowy DR, Mock BA.
p16 INK4a gene promoter variation and differential binding of a repressor, the ras-responsive zinc-finger transcription factor, RREB.
Oncogene. 22: 2285-95, 2003.
13)  Toshchakov V, Jones BW, Lentschat A, Silva A, Perera PY, Thomas K, Cody MJ, Zhang S, Williams BR, Major J, Hamilton TA, Fenton MJ, Vogel SN.
TLR2 and TLR4 agonists stimulate unique repertoires of host resistance genes in murine macrophages: interferon-beta-dependent signaling in TLR4-mediated responses.
J. Endotoxin Res. 9: 169-75, 2003.
14)  Zhang S, Thomas K, Blanco JC, Salkowski CA, Vogel SN.
The role of the interferon regulatory factors, IRF-1 and IRF-2, in LPS-induced cyclooxygenase-2 (COX-2) expression in vivo and in vitro.
J. Endotoxin Res. 8: 379-88, 2002.
15)  Toshchakov V, Jones BW, Perera PY, Thomas K, Cody MJ, Zhang S, Williams BR, Major J, Hamilton TA, Fenton MJ, Vogel SN.
TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages.
Nat. Immunol. 3: 392-8, 2002.
16)  Zhang SL, DuBois W, Ramsay ES, Bliskovski V, Morse HC, Taddesse-Heath L, Vass WC, DePinho RA, Mock BA.
Efficiency alleles of the Pctr1 modifier locus for plasmacytoma susceptibility.
Mol. Cell. Biol. 21: 310-8, 2001.
17)  Zhang S, Yu J, Cheng X, Ding L, Heng F, Wu N, Shen Y.
Regulation of human hsp90 alpha gene expression.
FEBS Letters. 444: 130-135, 1999.
18)  Zhang S, Mock BA.
The role of p16INK4a (Cdkn2a) in mouse plasma cell tumors.
Curr. Top. Microbiol. Immunol. 246: 363-7; discussion 368, 1999.
19)  Zhang S, Ramsay ES, Mock BA.
Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1.
Proc. Natl. Acad. Sci. U.S.A. 95: 2429-34, 1998.
Click Here to View Collapsed Bibliography.

This page was last updated on 7/11/2014.